Profile of omalizumab in the treatment of chronic spontaneous urticaria

Drug Design, Development and Therapy
Moises Labrador-Horrillo, Marta Ferrer

Abstract

Chronic spontaneous urticaria (CSU) is a disease with significant morbidity and relative prevalence that has important effects on the quality of life (QoL) of those who suffer from it. Omalizumab is a recombinant humanized anti-immunoglobulin E (IgE) antibody that binds to the Cε3 domain of the IgE heavy chain and prevents it from binding to its high-affinity receptor FcεRI. It has been largely studied in the field of asthma and is currently approved for the treatment of both adult and pediatric (children; >6-year-old) patients. In addition, in recent, well-controlled clinical trials in patients with CSU resistant to antihistamines, add-on therapy with subcutaneous omalizumab significantly reduced the severity of itching, and the number and size of hives, and increased patients' health-related QoL and the proportion of days free from angioedema compared with placebo, with an excellent tolerance. Thus, omalizumab is an effective and well-tolerated add-on therapy for patients with CSU who are symptomatic despite background therapy with H1 antihistamines. In this review, we cover the following points: epidemiology, pathogenesis, assessment of activity, impact on QoL, and treatment of CSU, and finally, we focus on omalizumab in the...Continue Reading

Citations

Jul 9, 2016·The Journal of Dermatological Treatment·Kanokvalai KulthananChanida Ungaksornpairote
Nov 22, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·M González-MedinaA Giménez-Arnau
Sep 30, 2020·Expert Opinion on Pharmacotherapy·Kam Lun HonVivian W Y Lee
Mar 30, 2019·Recent Patents on Inflammation & Allergy Drug Discovery·Kam L HonSteven K Loo
Jul 22, 2020·International Journal of Immunopathology and Pharmacology·Jakub Novosad, Irena Krčmová
Jan 23, 2021·Annales de dermatologie et de vénéréologie·M SarrazinS Duvert-Lehembre
Nov 12, 2020·Case Reports in Dermatology·Laura Michelina LosappioElide Anna Pastorello

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy
ISS

Clinical Trials Mentioned

NCT00866788
NCT01292473
NCT01264939
NCT01287117

Software Mentioned

MYSTIQUE

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

© 2021 Meta ULC. All rights reserved